Varicella zoster virus ocular disease

International Ophthalmology Clinics

Volumn 38, Issue 4, 1998, Pages 149-160

  Chern, Kenneth C ^a   Margolis, Todd P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2 INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; FAMCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; PENCICLOVIR; SORIVUDINE; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

CORTICOSTEROID THERAPY; HERPES ZOSTER OPHTHALMICUS; HUMAN; INCIDENCE; KERATITIS; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; REVIEW; TOPICAL DRUG ADMINISTRATION; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HERPES ZOSTER OPHTHALMICUS; HERPESVIRUS 3, HUMAN; HUMANS; KERATITIS; UVEITIS;

EID: 0032415923     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199803840-00014     Document Type: Review

References (66)

1. Marsh RJ, Cooper M. Ophthalmic herpes zoster. Eye 1993;7:350-370
2. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-316
3. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-1609
4. Strommen GL, Pucino F, Tight RR, et al. Human infection with herpes zoster: etiology, pathophysiology, clinical course, and treatment. Pharmacotherapy 1988;8:52-68
5. Straus SE, Ostrove JM, Inchauspe G, et al. NIH conference. Varicella-zoster virus infections: biology, natural history, treatment, and prevention. Ann Intern Med 1988;108: 221-237
6. Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly boosting with varicella vaccine. J Infect Dis 1984;149:647
7. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-381
8. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:370-375
9. Power WJ, Hogan RN, Hu S, et al. Primary varicella-zoster keratitis: diagnosis by polymerase chain reaction. Am J Ophthalmol 1997;123:252-254
10. Nishi M, Hanashiro R, Mori S, et al. Polymerase chain reaction for the detection of the varicella-zoster genome in ocular samples from patients with acute retinal necrosis. Am J Ophthalmol 1992;114:603-609
11. Short GA, Margolis TP, Kuppermann BD, et al. A polymerase chain reaction-based assay for diagnosing varicella-zoster virus retinitis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1997;123:157-164
12. Edgerton A. Herpes zoster ophthalmicus. Arch Ophthalmol 1945;34:40
13. Harding SP. Management of ophthalmic zoster. J Med Virol 1993;suppl 1:97-101
14. Castanet J, Rodot S, Lacour JP, et al. Chronic varicella presenting as disseminated pin-point-sized papules in a man infected with the human immunodeficiency virus. Dermatology 1996;192:84-86
15. Tappero JW, Perkins BA, Wenger JD, et al. Cutaneous manifestations of opportunistic infections in patients with human immunodeficiency virus. Clin Microbiol Rev 1995;8: 440-450
16. Colebunders R, Van Damme L, Van den Abbeele K, et al. Atypical varicella zoster infection in persons with HIV infection. Acta Clin Belg 1994;49:104-107
17. Petrozza JC, Monga M, Oshiro BT, et al. Disseminated herpes zoster in a pregnant woman positive for human immunodeficiency virus. Am J Perinatol 1993;10:463-464
18. Lewis G. Zoster sine herpete. Br Med J 1958;2:418-421
19. Easton HG. Zoster sine herpete causing acute trigeminal neuralgia. Lancet 1970;2: 1065-1066
20. Gilden DH, Dueland AN, Devlin ME, et al. Varicella-zoster virus reactivation without rash. J Infect Dis 1992;166(suppl 1):S30-34
21. Gilden DH, Wright RR, Schneck SA, et al. Zoster sine herpete, a clinical variant. Ann Neurol 1994;35:530-533
22. Ross JVM. Herpes zoster ophthalmicus sine eruptione. Arch Ophthalmol 1949;42: 808-812
23. Silverstein BE, Chandler D, Neger R, et al. Disciform keratitis: a case of herpes zoster sine herpete. Am J Ophthalmol 1997;123:254-255
24. Stavrou P, Mitchell SM, Fox JD, et al. Detection of varicella-zoster virus DNA in ocular samples from patients with uveitis but no cutaneous eruption. Eye 1994;8:684-687
25. Yamamoto S, Tada R, Shimomura Y, et al. Detecting varicella-zoster virus DNA in iridocyclitis using polymerase chain reaction: a case of zoster sine herpete. Arch Ophthalmol 1995;113:1358-1359
26. Schwab IR. Herpes zoster sine herpete. A potential cause of iridoplegic granulomatous iridocyclitis. Ophthalmology 1997;104:1421-1425
27. Pavan-Langston D, Yamamoto S, Dunkel EC. Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. Arch Ophthalmol 1995;113:1381-1385
28. Mietz H, Eis-Hubinger AM, Sundmacher R, et al. Detection of varicella-zoster virus DNA in keratectomy specimens by use of the polymerase chain reaction. Arch Ophthalmol 1997;115:590-594
29. Hoppenjans WB, Bibler MR, Orme RL, et al. Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome. Arch Dermatol 1990;126:1048-1050
30. Vaughan Jones SA, McGibbon DH, Bradbeer CS. Chronic verrucous varicella-zoster infection in a patient with AIDS. Clin Exp Dermatol 1994;19:327-329
31. LeBoit PE, Limova M, Yen TS, et al. Chronic verrucous varicella-zoster virus infection in patients with the acquired immunodeficiency syndrome (AIDS). Histologic and molecular biologic findings. Am J Dermatopathol 1992;14:1-7
32. Engstrom RE, Holland GN. Chronic herpes zoster virus keratitis associated with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988;105:556-558
33. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes: randomized, placebo-controlled trial. The National Institute of Allergy Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125:376-383
34. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22:341-347
35. O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37:233-309
36. Straus SE. Shingles. Sorrows, salves, and solutions. JAMA 1993;269:1836-1839
37. Haefeli WE, Schoenenberger RA, Weiss P, et al. Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose. Am J Med 1993;94:212-215
38. Aylward GW, Claoue CM, Marsh RJ, et al. Influence of oral acyclovir on ocular complications of herpes zoster ophthalmicus. Eye 1994;8:70-74
39. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763-770
40. Wallace MR, Bowler WA, Oldfield EC, III. Treatment of varicella in the immunocompetent adult. J Med Virol 1993;suppl 1:90-92
41. Hoang-Xuan T, Buchi ER, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology 1992;99:1062-1070
42. Neoh C, Harding SP, Saunders D, et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye 1994;8:688-691
43. Marsh RJ, Cooper M. Double-masked trial of topical acyclovir and steroids in the treatment of herpes zoster ocular inflammation. Br J Ophthalmol 1991;75:542-546
44. Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:187-191
45. Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994;170:68-75
46. Balfour HHJr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994;7:254-260
47. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997;31:185-191
48. Herne K, Cirelli R, Lee P, et al. Antiviral therapy of acute herpes zoster in older patients. Drugs Aging 1996;8:97-112
49. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123:89-96
50. Shigeta S, Yokota T, Iwabuchi T, et al. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 1983;147:576-581
51. Bodsworth NJ, Boag F, Burdge D, et al. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. J Infect Dis 1997;176: 103-111
52. Pinnolis MK, Foxworthy D, Kemp B. Treatment of progressive outer retinal necrosis with sorivudine. Am J Ophthalmol 1995;119:516-517
53. Wunderli W, Miner R, Wintsch J, et al. Outer retinal necrosis due to a strain of varicella-zoster virus resistant to acyclovir, ganciclovir, and sorivudine. Clin Infect Dis 1996;22: 864-865
54. Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25:270-273
55. Arvin AM, Kushner JH, Feldman S, et al. Human leukocyte Interferon for the treatment of varicella in children with cancer. N Engl J Med 1982;306:761-765
56. Merigan TC, Rand KH, Pollard RB, et al. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med 1978;298:981-987
57. Zaia JA, Levin MJ, Wright GG, et al. A practical method for preparation of varicella-zoster immune globulin. J Infect Dis 1978;137:601-604
58. Balfour HH Jr, Groth KE, McCullough J, et al. Prevention or modification of varicella using zoster immune plasma. Am J Dis Child 1977;131:693-696
59. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984;310:1409-1415
60. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live vaccine. Vaccine 1991;9:111-116
61. Levin MJ, Murray M, Rotbart HA, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-259
62. Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990;161:661-666
63. Hammerschlag MR, Gershon AA, Steinberg SP, et al. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis 1989;160:535-537
64. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176:578-585
65. Vafai A. Antibody-binding sites on truncated forms of varicella-zoster virus glycoprotein. Vaccine 1994;12:1265-1269
66. Vafai A. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine 1995;13:1336-1338